Physician profile
Arnold E Barz
NPI 1710972559
$7,050.09
in general payments reported to CMS, 2019-2025
28 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $514 · 2021: $950 · 2022: $1,270 · 2023: $828 · 2024: $1,308 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,148.23 |
| Education | $291.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $1,653.69 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals Lp | $653.93 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $624.05 | 2019-2025 | Tavneos, Krystexxa |
| Opko Pharmaceuticals, LLC | $474.57 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $427.48 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $403.86 | 2019-2024 | Auryxia, Vafseo |
| Glaxosmithkline, LLC. | $375.70 | 2020-2024 | Benlysta |
| Travere Therapeutics, INC. | $320.95 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $320.93 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $266.93 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $244.30 | 2019-2025 | Veltassa |
| Horizon Therapeutics Plc | $224.43 | 2021-2023 | Krystexxa |
| Daiichi Sankyo INC. | $213.57 | 2020-2024 | Injectafer |
| Shire North American Group INC | $167.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $144.29 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $75.39 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $70.65 | 2019-2025 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $57.34 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $53.11 | 2019 | |
| Calliditas Therapeutics US INC. | $51.43 | 2023 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $44.24 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $35.53 | 2024-2025 | Rybelsus, Ozempic |
| Pharmacyclics LLC, An Abbvie Company | $33.67 | 2023 | Imbruvica |
| Scpharmaceuticals INC. | $33.51 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.85 | 2025 | |
| Recor Medical INC | $18.55 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.96 | 2024 | Jardiance |
| Amag Pharmaceuticals, INC. | $17.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Barz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.